Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial

NCT06791460 is registered in ClinicalTrials.gov with Obstetrics & Gynecology Hospital of Fudan University as lead sponsor.

NCT NCT06791460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06791460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial
Lead sponsor
Obstetrics & Gynecology Hospital of Fudan University
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 18, 2025
Completion date
February 14, 2030
Enrollment
296 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer recurrent